Results 121 to 130 of about 14,856,300 (187)

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma. [PDF]

Blood Adv
Khan N, Dahi PB, Khimani F, Shustov AR, Shadman M, Ruan J, Moskowitz AJ, Zelenetz AD, Noy A, Straus DJ, Drullinsky P, Hamilton A, Kumar A, Sauter CS, Shah GL, Matasar MJ, Drill E, Davey T, Hancock H, Ganesan N, Galasso N, van Beisen K, Giralt S, Horwitz SM.   +23 more
europepmc   +1 more source

Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study. [PDF]

J Dtsch Dermatol Ges
Glatzel C, Hansen-Abeck I, Booken N, Düll J, Goebeler M, Schummer P, Wobser M.   +6 more
europepmc   +1 more source

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database. [PDF]

J Pharm Health Care Sci
Takatsu N, Matsumoto J, Oka Y, Sakai T, Iwata N, Higashionna T, Takeda T, Hamano H, Zamami Y.   +8 more
europepmc   +1 more source

Response to Comment on "Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma". [PDF]

J Clin Pharmacol
Inoue H, Wang X, Garcia R, Reilly B, Tachibana M, Yoo Y, Lau Y, Chen Y.   +7 more
europepmc   +1 more source

Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma. [PDF]

Front Immunol
Huang L, Guo H, Teng Y, Pang D, Zhang F, Sun Y, Ong CK, Tan J, Li W.   +8 more
europepmc   +1 more source

USP1-TRAF2 axis-regulated mortalin stability mediates chemoresistance by disrupting calcium transport in peripheral T-cell lymphoma. [PDF]

Proc Natl Acad Sci U S A
Gui A, Yan Y, Jiang S, Chen F, Zhou X, Sun Q, Qiu S, Wu J, Li X, Zhang J, Liu J, Zhu S, Wang L, Liu W, Zuo J, Zhang Q, Yang L.   +16 more
europepmc   +1 more source

Peripheral T-cell lymphoma of the lip: a rare case unveiling key insights into diagnosis and management. [PDF]

Ecancermedicalscience
Ali T, Khan L, Qureshi BM, Hafiz A, Tariq M, Minhas K, Ali N, Abbasi AN.   +7 more
europepmc   +1 more source

Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy. [PDF]

Int J Hematol
Tatetsu H, Kato K, Wada A, Hirano T, Ueno S, Miyasato Y, Yamada A, Shichijo T, Higuchi Y, Ueda Y, Nosaka K, Mikami Y, Karube K, Matsuoka M, Yasunaga JI.   +14 more
europepmc   +1 more source

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup. [PDF]

Sci Adv
Lone WG, Yu J, Liu X, Jochum DT, Bouska A, Shetty K, Herek T, Sharma S, Bi C, Shah R, Nasser ZW, Amador C, Arif A, Mir AR, Li Y, Heavican-Foral TB, Robinson J, Hyde RK, Sakata-Yanagimoto M, Rachagani S, McKeithan TW, Scott DW, Staudt LM, Inghirami G, Feldman A, Greiner T, Vose JM, Rimsza L, Khoury J, Chan WC, Iqbal J, Lymphoma/Leukemia Molecular Profiling Project (LLMPP).   +31 more
europepmc   +1 more source

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma. [PDF]

Blood Adv
Iyer S, Mehta-Shah N, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Alpdogan O, Feldman TA, Camus V, Gritti G, Zinzani PL, Belada D, Mayer J, Choi I, Cheong JW, Rustia E, Fenton K, Fanale M, Savage KJ, Horwitz SM.   +22 more
europepmc   +1 more source